secwatch.observer — SEC 8-K summary
======================================

Issuer:     Opus Genetics, Inc. (IRD)
CIK:        0001228627
Form:       8-K
Filed at:   2025-03-31T23:59:59+00:00
Accession:  0001140361-25-011181
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Opus Genetics reports FY2024 net loss of $57.5M; gene therapy pipeline advances
-------------------------------------------------------------------------------

- Net loss of $57.5M ($2.15/sh) vs $10.0M in 2023; revenue $11M from Viatris license.
- Cash $30.3M at year-end; March 2025 financing raised $21.5M, extending runway into H2 2026.
- OPGx-LCA5 Phase 1/2 shows durable response at 12 months; Type D FDA meeting held; pediatric enrollment started.
- OPGx-BEST1 IND-enabling studies done; Phase 1/2 initiation planned for 2025 with preliminary data by Q1 2026.
- Phentolamine LYNX-2 (dim light) and VEGA-3 (presbyopia) Phase 3 trials fully enrolled; topline data expected mid-2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1228627/000114036125011181/0001140361-25-011181-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1228627/000114036125011181/ef20046473_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-011181

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer